8-K: Novavax Settles Dispute with Gavi, Agrees to $475 Million Payment

Novavax has reached a settlement with Gavi, terminating their prior agreement and agreeing to a $475 million payment, including an initial payment and deferred annual payments.

Summary

• Novavax and Gavi have entered into a Termination and Settlement Agreement, resolving a dispute over a prior supply agreement for Novavax's COVID-19 vaccine.
• The settlement terminates the Advance Purchase Agreement (APA) from May 5, 2021, and settles arbitration proceedings initiated by Gavi.
• Novavax will pay Gavi a total of $475 million, consisting of an initial payment of $75 million made on February 20, 2024, and $400 million in deferred payments.
• The deferred payments will be made in equal annual installments of $80 million through December 31, 2028, with variable quarterly installments starting in the first quarter of 2024.
• Gavi may reduce the deferred payments by using an annual vaccine credit, equivalent to the unpaid balance, applicable to qualifying sales of Novavax vaccines to low-income and lower-middle income countries.
• Novavax has the discretion to price vaccines offered to these countries, and the actual price paid will be credited against the applicable credit.
• Novavax has also granted Gavi an additional credit of up to $225 million, applicable to qualifying sales exceeding the $80 million annual deferred payment amount.
• Novavax has granted Gavi a security interest in accounts receivable from Serum Institute of India related to the Matrix-M adjuvant for a malaria vaccine, which will continue for the deferred payment term.

Sentiment

Score: 4

Explanation: The settlement resolves a dispute but at a significant financial cost to Novavax, which is a negative development. The potential for future sales to offset the cost is uncertain.

Positives

• The settlement resolves a dispute with Gavi, removing uncertainty and potential legal costs.
• The agreement allows Novavax to potentially reduce its payment obligations through vaccine sales to low-income and lower-middle income countries.
• The security interest granted to Gavi is limited to accounts receivable from Serum Institute of India, not all company assets.

Negatives

• Novavax is obligated to pay $475 million to Gavi, which will impact its cash flow.
• The deferred payments of $80 million annually through 2028 represent a significant financial commitment.
• The company has granted a security interest in accounts receivable from Serum Institute of India, which could be a risk if those receivables are not realized.

Risks

• The company's ability to generate sufficient vaccine sales to low-income and lower-middle income countries to offset the deferred payments is uncertain.
• The security interest granted to Gavi could pose a risk if Serum Institute of India fails to meet its payment obligations.
• The settlement agreement could impact the company's financial performance and cash flow for the next several years.

Future Outlook

The company will need to manage its cash flow carefully to meet the settlement obligations and will need to focus on sales to low-income and lower-middle income countries to reduce the deferred payments.

Industry Context

This settlement reflects the challenges faced by vaccine manufacturers in managing supply agreements and demand fluctuations post-pandemic. It highlights the importance of flexible agreements and the need to adapt to changing market conditions.

Comparison to Industry Standards

• The settlement is similar to other renegotiations of vaccine supply agreements seen in the industry, where companies have had to adjust to lower demand than initially anticipated.
• Other vaccine manufacturers have also faced challenges with excess inventory and have had to write down the value of their vaccine stocks.
• The use of vaccine credits to offset payment obligations is a mechanism that has been used in other similar agreements.

Stakeholder Impact

• Shareholders will be impacted by the financial obligations of the settlement.
• Employees may be affected by the company's financial performance.
• Customers in low-income and lower-middle income countries may benefit from access to Novavax vaccines through the vaccine credit program.
• Creditors may be impacted by the company's increased debt obligations.

Next Steps

• Novavax will make the initial settlement payment of $75 million.
• Novavax will begin making deferred payments in quarterly installments starting in the first quarter of 2024.
• Novavax will work to generate vaccine sales to low-income and lower-middle income countries to utilize the vaccine credits.
• The Settlement Agreement will be filed as an exhibit to the company's Annual Report on Form 10-K for the year ended December 31, 2023.

Key Dates

Keywords

Novavax, Gavi, Settlement Agreement, COVID-19 Vaccine, Advance Purchase Agreement, Arbitration, Deferred Payments, Vaccine Credit, Serum Institute of India, Matrix-M Adjuvant